Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

• ClinicalTrials.gov Identifier: NCT01363908
• Recruitment Status: Terminated
• First Posted: June 2, 2011
• Results First Posted: May 27, 2015
• Last Update Posted: June 14, 2021
• Sponsor: Shire
• Information provided by (Responsible Party): Takeda ( Shire )

Tracking Information

• First Submitted Date: May 30, 2011
• First Posted Date: June 2, 2011
• Results First Submitted Date: May 6, 2015
• Results First Posted Date: May 27, 2015
• Last Update Posted Date: June 14, 2021
• Actual Study Start Date: August 10, 2011
• Actual Primary Completion Date: May 13, 2014 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 27, 2015)

• Maximum Observed Plasma Concentration (Cmax) of SPD602 After a Single Oral Dose [ Time Frame: Day 1 and up to 24 hours post-dose ]
  The pharmacokinetic (PK) parameters of SPD602 were measured in plasma of all patients following a single capsule dose of SPD602 at 16 mg/kg at start of treatment on Day 1 and at the clinic visit on Day 2. PK blood samples were collected as follows: Pre-dose on Day 1 (within 60 minutes prior to investigational product administration) and at 0.5, 1, 2, 3, 4, 8 hours (±3 minutes) and 24 hours (±30 minutes) post-dose. Plasma concentrations of SPD602 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The PK parameters were determined from plasma concentration-time data for SPD602 (total) by non-compartmental analysis.
• Time of Maximum Observed Plasma Concentration Sampled During a Dosing Interval (Tmax) of SPD602 After a Single Oral Dose [ Time Frame: Day 1 and up to 24 hours post-dose ]
  The pharmacokinetic (PK) parameters of SPD602 were measured in plasma of all patients following a single capsule dose of SPD602 at 16 mg/kg at start of treatment on Day 1 and at the clinic visit on Day 2. PK blood samples were collected as follows: Pre-dose on Day 1 (within 60 minutes prior to investigational product administration) and at 0.5, 1, 2, 3, 4, 8 hours (±3 minutes) and 24 hours (±30 minutes) post-dose. Plasma concentrations of SPD602 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The PK parameters were determined from plasma concentration-time data for SPD602 (total) by non-compartmental analysis.
• Area Under The Plasma Concentration-Time Curve (AUC) From The Time of Dosing to The Last Measurable Concentration (AUClast) of SPD602 After a Single Oral Dose [ Time Frame: Day 1 and up to 24 hours post-dose ]
  The pharmacokinetic (PK) parameters of SPD602 were measured in plasma of all patients following a single capsule dose of SPD602 at 16 mg/kg at start of treatment on Day 1 and at the clinic visit on Day 2. PK blood samples were collected as follows: Pre-dose on Day 1 (within 60 minutes prior to investigational product administration) and at 0.5, 1, 2, 3, 4, 8 hours (±3 minutes) and 24 hours (±30 minutes) post-dose. Plasma concentrations of SPD602 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The PK parameters were determined from plasma concentration-time data for SPD602 (total) by non-compartmental analysis.
• Terminal Half-life (t1/2) of SPD602 After a Single Oral Dose [ Time Frame: Day 1 and up to 24 hours post-dose ]
  The pharmacokinetic (PK) parameters of SPD602 were measured in plasma of all patients following a single capsule dose of SPD602 at 16 mg/kg at start of treatment on Day 1 and at the clinic visit on Day 2. PK blood samples were collected as follows: Pre-dose on Day 1 (within 60 minutes prior to investigational product administration) and at 0.5, 1, 2, 3, 4, 8 hours (±3 minutes) and 24 hours (±30 minutes) post-dose. Plasma concentrations of SPD602 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The PK parameters were determined from plasma concentration-time data for SPD602 (total) by non-compartmental analysis.
• Renal Clearance (CLr) of SPD602 After a Single Oral Dose [ Time Frame: Day 1 and up to 24 hours post-dose ]
  The pharmacokinetic (PK) parameters of SPD602 were measured in urine of patients following a single capsule dose of SPD602 at 16 mg/kg at start of treatment on Day 1 and at the clinic visit on Day 2. Children who could cooperate provided urine samples for PK assessment on Day 1 over 3 time intervals: 0-4, 4-8, and 8-24 hours after the last dose (continued into Day 2). Urine concentrations of SPD602 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The PK parameters were determined from urine concentration-time data for SPD602 (total) by non-compartmental analysis.
• Amount Excreted Into Urine (Ue) of SPD602 After a Single Oral Dose [ Time Frame: Day 1 and up to 24 hours post-dose ]
  The pharmacokinetic (PK) parameters of SPD602 were measured in urine of patients following a single capsule dose of SPD602 at 16 mg/kg at start of treatment on Day 1 and at the clinic visit on Day 2. Children who could cooperate provided urine samples for PK assessment on Day 1 over 3 time intervals: 0-4, 4-8, and 8-24 hours after the last dose (continued into Day 2). Urine concentrations of SPD602 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The PK parameters were determined from urine concentration-time data for SPD602 (total) by non-compartmental analysis.
• Fraction Of Orally Administered Drug Excreted Unchanged In Urine (fe) of SPD602 After a Single Oral Dose [ Time Frame: Day 1 and up to 24 hours post-dose ]
  The pharmacokinetic (PK) parameters of SPD602 were measured in urine of patients following a single capsule dose of SPD602 at 16 mg/kg at start of treatment on Day 1 and at the clinic visit on Day 2. Children who could cooperate provided urine samples for PK assessment on Day 1 over 3 time intervals: 0-4, 4-8, and 8-24 hours after the last dose (continued into Day 2). Urine concentrations of SPD602 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The PK parameters were determined from urine concentration-time data for SPD602 (total) by non-compartmental analysis.
• Change From Baseline in Liver Iron Concentration (LIC) Assessed by FerriScan R2 Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline, 24 weeks, and 48 weeks ]
  The efficacy of SPD602 was assessed by determining LIC. Abdominal MRI data were collected by using FerriScan R2 standard procedures and used to determine LIC. A negative change from baseline indicates that LIC decreased.
• Change From Baseline in LIC Adjusted by Transfusional Iron Intake And Assessed by FerriScan R2 MRI [ Time Frame: Baseline, 24 weeks, and 48 weeks ]
  The efficacy of SPD602 was assessed by determining LIC and adjusting for transfusional iron intake. Abdominal MRI data were collected by using FerriScan R2 standard procedures and used to determine LIC. A negative change from baseline indicates that LIC decreased.

Original Primary Outcome Measures (submitted: May 31, 2011)

• Single-dose Pharmacokinetics: The concentrations of FBS0701 will be measured in plasma from all patients using a validated assay method. Pharmacokinetic parameters will be tabulated and summarized. [ Time Frame: 8 days ]
  Plasma levels, half-life of FBS0701 and other pharmacokinetic parameters following a single capsule dose of FBS0701 at 16 mg/kg with 7 days of follow-up.
• Multiple Dose FBS0701 Study: Safety and Tolerability Based on Clinical Assessments; Efficacy Based on Clinical Response [ Time Frame: 48 weeks ]
  Clinical assessments include incidence and severity of adverse events, physical examinations including vital signs, clinical laboratory values, and ECGs); clinical response to be evaluated based on changes in liver and cardiac iron concentration determined by MRI in patients able to be studied using this method; serum ferritin in all patients.

Current Secondary Outcome Measures (submitted: May 27, 2015)

• Change From Baseline in LIC Assessed by R2* MRI [ Time Frame: Baseline, 24 weeks, and 48 weeks ]
  The efficacy of SPD602 was assessed by determining LIC. Abdominal MRI data were collected by using R2* standard procedures and used to determine LIC. A negative change from baseline indicates that LIC decreased.
• Change From Baseline in LIC Adjusted by Transfusional Iron Intake And Assessed by R2* MRI [ Time Frame: Baseline, 24 weeks, and 48 weeks ]
  The efficacy of SPD602 was assessed by determining LIC and adjusting for transfusional iron intake. Abdominal MRI data were collected by using R2* standard procedures and used to determine LIC. A negative change from baseline indicates that LIC decreased.
• Change From Baseline in Cardiac Iron Load Assessed by T2* MRI [ Time Frame: Baseline, 24 weeks, and 48 weeks ]
  The efficacy of SPD602 was assessed by determining cardiac iron load. Cardiac MRI data were collected by using T2* standard procedures and used to determine iron load. A negative change from baseline indicates that iron load increased.
• Change From Baseline in Serum Ferritin [ Time Frame: Baseline, 24 weeks, and 48 weeks ]
  Serum ferritin levels were assessed to determine if a participant was a successful responder and were determined from serum biochemistry analyses conducted at the central laboratories. A negative change from baseline indicates that serum ferritin decreased.

• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
• Official Title: A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload
• Brief Summary: This is an open-label study to assess the pharmacokinetics, safety, efficacy and tolerability of SSP-004184AQ. The study consists of two phases: the pharmacokinetic phase, using a single 16 mg/kg dose of SSP-004184AQ; and the chronic dosing phase, during which patients will receive an additional 48 weeks of SSP-004184AQ dosing. Two age groups will be studied: 6-<12, and 12-<18 years old. The study is designed to initially assess the pharmacokinetics and safety of SSP-004184AQ in older children (adolescents, 12-<18 years old) and then if deemed safe, in younger children (6-<12 years old).

Detailed Description

Pharmacokinetic Phase: Patients will receive a single 16 mg/kg dose of SSP-004184AQ in capsule form.

Chronic Dosing Phase: Patients will receive SSP-004184AQ capsules daily for 48 weeks. Doses may range from 8-60 mg/kg/d.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Non-Randomized; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Transfusional Iron Overload
• Beta-Thalassemia

Intervention

Drug: SPD602

Other Name: SSP-004184, deferitazole

Study Arms

• Experimental: SPD602 (26 mg/kg)
  Oral SSP-004184AQ taken once daily for 48 weeks
  Intervention: Drug: SPD602
• Experimental: SPD602 (36 mg/kg)
  Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.
  Intervention: Drug: SPD602
• Experimental: SPD602 (16 mg/kg)
  A single dose given in the initial pharmacokinetic phase.
  Intervention: Drug: SPD602

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: May 31, 2011): 30
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: May 13, 2014
• Actual Primary Completion Date: May 13, 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria

• Parents willing and able to sign the approved informed consent for their children and subjects between the ages of 6 and <18 years willing and able to provide their assent (based on institutional guidelines).
• Able to swallow whole capsules.
• Age >6 and <18 years.
• Transfusion-dependent subjects who have transfusional iron overload requiring chronic treatment with deferoxamine, deferasirox, or deferiprone. A transfusion dependent subject is defined in this study as one with a minimum transfusion history totaling more than 20 units of packed red blood cells OR a calculated iron load based on transfusion history of 200mg/kg AND a transfusion requirement of 7 or more transfusions per year; or, in subjects with sickle cell anemia, be iron overloaded but can be receiving transfusion exchange therapy in lieu of transfusions.
• In the opinion of the Investigator (and in consultation with the subject's parents), the subject is able to discontinue all existing iron chelation therapies for a minimum period of 1-5 days prior first dose of SSP-004184AQ, for the initial pharmacokinetic period of 8 days (if applicable), and for up to 49 weeks if continuing into the chronic dosing phase.

• Subjects able to have an MRI must have:

  1. liver iron concentration >2 and <30mg/g (dry weight, liver) by FerriScan® R2
  2. cardiac MRI T2* >10ms (Note: Subjects not able to have an MRI will be considered iron overloaded on the basis of serum ferritin only.)
• Serum ferritin >500ng/mL at Screening.
• Mean of the previous 3 pre-transfusion hemoglobin concentrations greater than or equal to 7.5g/dL.
• If appropriate, depending on age, female subjects of child-bearing potential need to use a medically acceptable method for birth control from screening until 30 days after the last dose of the study drug. Females of child-bearing potential must have a negative serum beta-HCG pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit. Females of child-bearing potential must agree to abstain from sexual activity that could result in pregnancy or agree to use acceptable methods of contraception.

Exclusion Criteria

• As a result of medical review, physical examination (including height and weight) or Screening investigations, the Principal Investigator considers the subject unfit for the study.
• Iron overload from causes other than transfusional hemosiderosis.
• Severe cardiac dysfunction.
• Non-elective hospitalization within the 30 days prior to Baseline testing.
• Evidence of clinically significant oral, cardiovascular, gastrointestinal, hepatic, biliary, renal, endocrine, pulmonary, neurologic, psychiatric, or skin disorder that contra-indicates dosing with SSP-004184AQ.
• Evidence of significant renal insufficiency, eg, serum creatinine above the upper limit of normal or proteinuria greater than 1 gm per day.
• Known sensitivity to any ingredient in the SSP-004184AQ formulation.
• Platelet count below 100,000/µL or absolute neutrophil count less than 1500/mm3 at Screening.
• ALT >180 IU/L at Screening.
• Use of any investigational agent within the 30 days prior to Baseline testing.
• Pregnant or lactating females.
• Cardiac left ventricular ejection fraction a) Below the locally determined normal range in the 12 months prior to screening by echocardiography or MRI or <50% at Baseline testing by MRI (echocardiograph is acceptable for LVEF if MRI information is not available).

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 6 Years to 17 Years (Child)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, Italy, Lebanon, Turkey, United States

Administrative Information

• NCT Number: NCT01363908
• Other Study ID Numbers: SPD602-202; SSP-004184AQ ( Other Identifier: Shire )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Takeda ( Shire )
• Original Responsible Party: Medical Monitor, FerroKin BioSciences, Inc.
• Current Study Sponsor: Shire
• Original Study Sponsor: FerroKin BioSciences, Inc.
• Collaborators: Not Provided

Investigators

• Study Director: Study Director; Takeda

• PRS Account: Takeda
• Verification Date: June 2021